CRCecília Maria Roteli-Martins

Cecília Maria Roteli-Martins

*This is an algorithmically generated author record based on publicly available information.

Cecília Maria Roteli-Martins has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine

    by Cecilia M. Roteli-Martins, Paulo Naud, Paola De Borba, Julio C. Teixeira, Newton S. De Carvalho, Toufik Zahaf, Nervo Sanchez, Brecht Geeraerts, Dominique Descamps

    Prophylactic human papillomavirus (HPV) vaccines are now available and vaccination programs are being widely implemented, targeting adolescent girls prior to sexual debut. Since the risk of HPV exposure persists throughout a woman’s sexual life, the duration of protection provided by vaccination is critical to the overall vaccine effectiveness. We report the long-term efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine (Cervarix®) up to 8.4 y after the first vaccine dose. In an initial placebo-controlled study performed in US, Canada and Brazil, women aged 15–25 y with normal cervical cytology, HPV-16/18 seronegative by ELISA, DNA-negative for 14 oncogenic HPV types by PCR, received either the HPV-16/18 vaccine or placebo (n = 1,113). Subjects were followed up to 6.4 y after the first dose (n = 776). We report an additional 2-y follow-up for women enrolled from the Brazilian centers from the initial study (n = 436). During the current follow-up study (HPV-023, NCT00518336), no new infection or lesions associated with HPV-16/18 occurred in the vaccine group. Vaccine efficacy over the entire follow-up (up to 8.4 y) was 95.1% (84.6, 99.0) for incident infection, 100% (79.8, 100) for 6-mo persistent infection, 100% (56.1, 100) for 12-mo persistent infection and 100% (< 0, 100) for CIN2+ associated with HPV-16/18. All women in the vaccine group remained seropositive to both HPV-16/18, with antibody titers for total and neutralizing antibodies remaining several-folds above natural infection levels. The safety profile was clinically acceptable for both vaccine and control groups. This is, to date, the longest follow-up study for a licensed cervical cancer vaccine.


  • Prevalence of Human Papillomavirus Infection and Associated Risk Factors in Young Women in Brazil, Canada, and the United States

    by Cecilia M. Roteli-Martins, Newton S. de Carvalho, Paulo Naud, Julio Teixeira, Paola Borba, Sophie Derchain, Stephen Tyring, Stanley Gall, Angela Diaz, Mark Blatter, et al.

    To determine the prevalence of cervical human papillomavirus (HPV) infection and risk factors in young women from Brazil, Canada, and the USA. Cross-sectional study in 3204 healthy women, aged 15 to 25 years. Cervical samples were collected for cytology and for HPV DNA detection (SPF10-LiPA25 system). Serum samples were collected for the measurement of HPV-16 and HPV-18 antibodies by enzyme-linked immunosorbent assay. Risk factors were obtained through a questionnaire. Overall, 26.6% of women had DNA detected for at least 1 HPV type. The prevalence for oncogenic HPV types was 21.7% (25% in Brazil, 16.9% in Canada, and 19.1% in the USA). HPV-16 was the most prevalent oncogenic type (5.2%). The next most common oncogenic HPV types were 51 (3.3%), 52 (3.3%), 31 (2.9%), 66 (2.3%), and 39 (2.0%). Multiple oncogenic types were detected in one-third of the infections. The prevalence of HPV-16 and/or HPV-18 infections detected by DNA and/or enzyme-linked immunosorbent assay was 24.8%. The majority of women (85%) had a normal cervical cytology. Sexual behavior was the main determinant for HPV-16/18 infections and squamous intraepithelial lesions. The prevalence of HPV oncogenic infections was high and linked to sexual behavior. Strategies to reduce the burden of oncogenic HPV infection, such as prophylactic vaccination programs, are likely to impact the burden of disease due to cervical precancer and cancer.


  • Open Access

    Associação entre idade ao início da atividade sexual e subseqüente infecção por papilomavírus humano: resultados de um programa de rastreamento brasileiro

    by Cecília Maria Roteli-Martins, Adhemar Longatto Filho, Luciano Serpa Hammes, Sophie Françoise Mauricette Derchain, Paulo Naud, Jean Carlos de Matos, Daniela Etlinger, Luis Sarian, Renata Clementino Gontijo, Marina Yoshiê Sakamoto Maeda, et al.

    OBJETIVO: descrever a idade de início da atividade sexual (sexarca) e a sua associação com a idade das mulheres com a infecção por papilomavírus humano (HPV) e com as alterações citológicas no exame de papanicolaou. MÉTODOS: mulheres da população geral foram recrutadas para participar de um estudo de rastreamento de câncer cervical e lesões pré-malignas. Após a aplicação de questionário comportamental, foram submetidas ao rastreamento com gia cervical e teste para DNA de HPV de alto risco, por meio de Captura Híbrida 2. Este projeto faz parte do Latin American Screening Study, que envolve mulheres do Brasil e da Argentina, e os dados aqui apresentados referem-se aos centros brasileiros nas cidades de Porto Alegre, São Paulo e Campinas. RESULTADOS: de 8.649 mulheres entrevistadas, 8.641 relataram atividade sexual prévia e foram incluídas na análise. A média de idade no momento da entrevista foi de 38,1±11,04 anos, com início da atividade sexual em média aos 18,5±4,0 anos. Identificamos que a idade do início da atividade sexual aumenta de acordo com o aumento da faixa etária no momento da entrevista, isto é, mulheres mais novas relataram sexarca mais precoce que mulheres mais velhas (p ou = ASC-US (6,7%) do que mulheres com sexarca em idade maior que a média (4,3%) - OR=1,6 (IC95%=1,3-2,0; p<0,001). CONCLUSÕES: a infecção por HPV e a presença de alterações citológicas identificadas no rastreio de lesões cervicais em uma população assintomática estiveram significativamente associadas à idade mais precoce no início das relações sexuais. Ademais, identificamos também que as mulheres desta amostra apresentaram diminuição da idade ao início da atividade sexual, nas últimas décadas, sugerindo importante causa para o acréscimo da prevalência de HPV e as lesões decorrentes desta infecção.


  • Value of Morphological Criteria in Diagnosing Cervical HPV Lesions Confirmed by in situ Hybridization and Hybrid Capture Assay

    by Cecilia M. Roteli-Martins, Venâncio A.F. Alves, R. Telma M. Santos, Edson Z. Martinez, Kari J. Syrjänen, Sophie F.M. Derchain